Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY:XBI)

84.83 +0.04 (+0.05%)
Streaming Delayed Price Updated: 10:39 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,071,902
Open 85.01
Bid (Size) 84.83 (10)
Ask (Size) 84.85 (1)
Prev. Close 84.79
Today's Range 84.42 - 85.25
52wk Range 66.66 - 105.47
Shares Outstanding 579,750
Dividend Yield 0.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages
ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according... 
Via Stocktwits
Topics ETFs Intellectual Property
Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning
The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review. 
Via Stocktwits

Performance

YTD
-7.3%
-7.3%
1 Month
+4.4%
+4.4%
3 Month
+5.3%
+5.3%
6 Month
-7.3%
-7.3%
1 Year
-7.1%
-7.1%

More News

Read More
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Via Stocktwits
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
Via Stocktwits
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
Via Stocktwits
Topics Lawsuit Regulatory Compliance
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
Via Stocktwits
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
Via Benzinga
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
Via Investor's Business Daily
Topics ETFs Government
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Via Benzinga
Best Biotech Stocks to Buy in 2025
Via MarketBeat
Topics ETFs Economy Government
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode
Via Stocktwits
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
Via Stocktwits
Topics Economy Government
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Via Talk Markets
Topics ETFs Stocks / Equities
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
Via Stocktwits
Topics Artificial Intelligence
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
Via Stocktwits
Topics Government Retirement Stocks
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic
Via Stocktwits
Topics Bankruptcy
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Via The Motley Fool
Topics ETFs
Is It A Good Time To Trade Small Cap Biotech Stocks? - 3 Steps To Consider
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Weakness Ahead?
Via Talk Markets
Topics ETFs
Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed.
Via Investor's Business Daily
Topics Economy Government World Trade
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
Via Stocktwits
Topics ETFs Government
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Via Investor's Business Daily
Topics Workforce
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Via Investor's Business Daily

Frequently Asked Questions

Is SPDR Series Trust SPDR S&P Biotech ETF publicly traded?
Yes, SPDR Series Trust SPDR S&P Biotech ETF is publicly traded.
What exchange does SPDR Series Trust SPDR S&P Biotech ETF trade on?
SPDR Series Trust SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF?
The ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of SPDR Series Trust SPDR S&P Biotech ETF?
The current price of SPDR Series Trust SPDR S&P Biotech ETF is 84.83
When was SPDR Series Trust SPDR S&P Biotech ETF last traded?
The last trade of SPDR Series Trust SPDR S&P Biotech ETF was at 07/03/25 10:39 AM ET
What is the market capitalization of SPDR Series Trust SPDR S&P Biotech ETF?
The market capitalization of SPDR Series Trust SPDR S&P Biotech ETF is 49.18M
How many shares of SPDR Series Trust SPDR S&P Biotech ETF are outstanding?
SPDR Series Trust SPDR S&P Biotech ETF has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.